2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
May 2024 in “Reactions weekly” October 2025 in “Frontiers in Toxicology” A new method effectively predicts estrogen-related health effects for early screening.
4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.
2 citations
,
January 2023 in “PubMed” Targeting FGF5 could help treat prostate cancer.
February 2020 in “Definitions” 5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.
December 2023 in “International Journal of Research in Ayurveda and Pharmacy” Ayurvedic remedies may boost immunity and balance in cancer treatment but need more research.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
September 2025 in “Jurnal Penelitian Pendidikan IPA” Two genetic variations in Moa buffalo help them adapt to heat.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
1 citations
,
February 2023 in “Pharmaceutics” Cell proteomic footprinting enhances cancer vaccine quality by ensuring correct antigen composition.
January 2023 in “Cutaneous and Ocular Toxicology” 20 citations
,
September 1983 in “Archives of dermatology” The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.
October 2025 in “CRC Press eBooks”
24 citations
,
July 2013 in “Oncologist” Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
56 citations
,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
23 citations
,
March 2014 in “International Journal of Molecular Sciences” Testosterone reduces knee flexibility by affecting relaxin receptors.
1 citations
,
February 2014 in “Archiv Der Pharmazie” Carbamates may help treat androgen-dependent conditions by changing how certain lipid enzymes are produced.
2 citations
,
May 2021 in “Journal of pharmaceutical and biomedical analysis” A new method was developed to accurately detect and measure 47 different drug ingredients in various products.
17 citations
,
August 2012 in “Journal of Medical Genetics” A new mutation in the XEDAR gene might cause a rare skin condition called hypohidrotic ectodermal dysplasia.
27 citations
,
July 1997 in “PubMed” The harlequin ichthyosis mouse mutation causes thick skin and early death, resembling a human skin disorder.
81 citations
,
March 1985 in “Journal of Clinical Investigation” Measuring 24-OHase induction helps identify defects in vitamin D processing and predict treatment response.
5 citations
,
January 2004 in “Biochimie” Arsenic trioxide effectively treats APL, improving survival rates despite its toxicity.
4 citations
,
February 2016 in “Clinical Pharmacology & Therapeutics” Hair follicle samples effectively show how well the drug MK-0752 targets and engages with the Notch pathway.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.